Global Actemra Shortages

Rheumatology patients forced to sacrifice their treatments to increase availability for hospitalized COVID-19 patients

Hospitalized COVID patients are being treated with Actemra (tocilizumab) causing a supply shortage impacting patients internationally. This ongoing ripple effect means that once again, AiArthritis and other high-risk patients are forced to deal with another wave of complications in managing their health because of COVID. This time in risking long term health due to lack of adequate treatment, along with unnecessary pain and anxiety. Unfortunately, in some cases, these risks and complications could have been prevented.

Rheumatology patients forced to sacrifice their treatments to increase availability for hospitalized COVID-19 patients


Autoimmune and Autoinflammatory Diseases that include inflammatory arthritis as a significant clinical component (AiArthritis Diseases) are full-body conditions affecting joints, tissues, and organs. Given these diseases are unique per individual, finding the right treatment can take months or years.


Autoimmune and Autoinflammatory Diseases that include inflammatory arthritis as a significant clinical component (AiArthritis Diseases) are full-body conditions affecting joints, tissues, and organs. Given these diseases are unique per individual, finding the right treatment can take months or years.


Most patients are prescribed disease-modifying antirheumatic drugs (DMARDs), including biologics, to manage their condition, but there’s no one-size-fits-all therapy, and responses vary per individual. The right therapy can be life-changing; disrupting continuity of care is strongly discouraged, as it can result in compromised quality of life, loss of employment, and comorbid diseases. 
But to accommodate hospital inventory needs due to high COVID hospitalization rates, mostly attributed to those not vaccinated , chronically ill rheumatology patients worldwide are being forced off their treatments…and they are angry.


Erin (USA), diagnosed age 14 with juvenile Psoriatic Arthritis, says, “Throughout the pandemic the public was asked to protect the at-risk population by washing their hands, socially distancing, wearing a mask, and getting vaccinated. Now the ‘at-risk’ people must protect some who didn’t do their part?” 


Bottom line: This situation was, and still can be, preventable. If more people choose vaccination, hospitalization rates would decrease, and rheumatology patients may not be forced to sacrifice the treatments that work best for them. 



Has this drug shortage impact you?

Tell us about it.

Contact Us

Help us spread the word!

Contact your local media outlets and let them know about the shortage.


  1. Choose a media outlet to contact. This can be your local new station or national broadcaster.
  2. Find out how to contact them. This should be on their website. You can also see if there is a reporter assigned to healthcare topics.
  3. Send them the Press Release. Use this link: https://www.pr.com/press-release/847662 and if you feel comfortable include why this issue matters to you, or how the shortage is impacting your life.
  4. Include contact details for AiArthritis: Katie Simons, Katie@AiArthritis.org, 877-609-4226


Related Projects

Share by: